Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference9 articles.
1. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B;Silverman;J Clin Oncol.,2002
2. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional cure regimens (CCR): results of the AZA-001 phase III study [abstract];Fenaux;Blood.,2007
3. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer.,2006
4. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia;Kantarjian;Blood.,2007
5. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience;Kantarjian;Cancer.,2007
Cited by 238 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024
2. Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents;British Journal of Haematology;2023-11-10
3. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches;Annals of Hematology;2023-09-28
4. Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study;Annals of Hematology;2023-09-08
5. EXABS-119-MDS An Update on Higher Risk Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3